| Species |
Canine |
| Protein Construction |
| His |
GDF15 (Ala197-Val307)
Accession # A0A8C0TNP6 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized GDF15, His, Canine at 1μg/ml (100μl/Well) on the plate can bind AntiGDF15 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
13.12 kDa |
| Apparent Molecular Weight |
The protein migrates to 15-20 kDa under reduced (R) condition and 23-26 kDa under Non reducing (N) condition based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 50mM HAc (pH 2.9). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 50mM HAc (pH 2.9). |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Growth Differentiation Factor 15 (GDF15), also known as NSAID activated gene-1 (NAG-1), is associated with a large number of biological processes and diseases, including cancer and obesity. GDF15 is synthesized as pro-GDF15, is dimerized, and is cleaved and secreted into the circulation as a mature dimer GDF15. |
| Synonyms |
GDF-15; MIC-1; NAG-1; PDF; PLAB; PTGFB; GDF15; MIC1; RG-1; Placental TGF-beta; PTGF-beta; PTGFBPTGF-beta; Placental TGF-β; PTGF-β; PTGFBPTGF-β |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
